Loading...
Loading...
Browse all stories on DeepNewz
VisitNew cancer diagnostic test developed from UK Biobank study by end of 2026?
Yes • 50%
No • 50%
Announcements from UK Biobank, peer-reviewed publications, or regulatory approvals
UK Biobank's Largest-Ever Study to Analyze 5,400 Proteins in 600,000 Samples
Jan 10, 2025, 01:52 PM
UK Biobank has launched the world's most comprehensive study of proteins circulating in the human body, aimed at transforming research into new medical tests, drugs, and treatments. The study, backed by a consortium of 14 biopharmaceutical companies, will measure up to 5,400 proteins in each of 600,000 samples, including initial and follow-up samples from half a million participants. The research will begin with analyzing 300,000 samples, starting with 250,000 initial samples and 50,000 follow-up samples taken up to 15 years later. The study utilizes the Olink Platform from Thermo Fisher Scientific and the UG 100™ Sequencing Platform from Ultima Genomics. This initiative is expected to lead to significant advancements in understanding disease mechanisms, biomarker discovery, and drug development, potentially revolutionizing healthcare by the end of the decade.
View original story
No • 50%
Yes • 50%
Yes • 50%
No • 50%
Trials not completed • 25%
Unsuccessful • 25%
Successful with some issues • 25%
Successful with no major issues • 25%
Yes • 50%
No • 50%
No coverage • 25%
Moderate coverage • 25%
Extensive coverage • 25%
Limited coverage • 25%
Yes • 50%
No • 50%
Minimal adoption (<25% countries) • 25%
Low adoption (25-49% countries) • 25%
Moderate adoption (50-74% countries) • 25%
High adoption (75%+ countries) • 25%
No • 50%
Yes • 50%
Other • 25%
USA • 25%
UK • 25%
Germany • 25%
AI-driven analysis • 25%
Radiocarbon dating advancements • 25%
Advanced DNA sequencing • 25%
Other technological breakthroughs • 25%
Rarely covered • 25%
Not covered • 25%
Widely covered • 25%
Partially covered • 25%
Roche • 25%
Pfizer • 25%
Other • 25%
Novartis • 25%
Neurodegenerative Diseases • 25%
Other • 25%
Cardiovascular Diseases • 25%
Cancer • 25%